# An Open Label Study of the Effects of SHR1459 in NMOSDs Patients

> **NCT04670770** · PHASE2 · COMPLETED · sponsor: **Reistone Biopharma Company Limited** · enrollment: 10 (actual)

## Conditions studied

- Neuromyelitis Optica Spectrum Disorders

## Interventions

- **DRUG:** Drug - SHR1459

## Key facts

- **NCT ID:** NCT04670770
- **Lead sponsor:** Reistone Biopharma Company Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-01-20
- **Primary completion:** 2022-08-15
- **Final completion:** 2022-08-15
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2023-03-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04670770

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04670770, "An Open Label Study of the Effects of SHR1459 in NMOSDs Patients". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT04670770. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*